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SummARy – The standard of treatment of metastatic hormone-sensitive prostate cancer  
(mhSpC) is androgen deprivation therapy (Adt) with docetaxel or abiraterone. however, numerous 
retrospective studies suggested outcome benefit of prostate radiotherapy. Small randomized trial 
(hoRRAd) showed no overall survival (oS) benefit of the addition of prostate radiotherapy to Adt 
but there was a trend toward survival benefit in a low volume disease. Although the results of large 
randomized study (StAmpede) have also not proved improvement of oS in unselected patients, 
robust improvement of failure-free survival was found. in addition, oS was significantly improved in 
patients with a low volume disease. in the absence of reliable molecular markers, the extent of meta-
static disease has emerged as an important factor for treatment decision making. in this review, we 
summarize data from non-randomized as well as from randomized studies concerning prostate radio-
therapy to contribute to the improvement of treatment tailoring for each individual patient with 
mhSpC in order to achieve the best possible treatment outcomes.
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Introduction
epidemiological data has suggested an increasing 
incidence of newly diagnosed metastatic hormone–
sensitive prostate cancer (mhSpC)1. Additionally, 
20–40% of patients undergoing radical prostatectomy2 
and 30–50% of patients undergoing primary radio-
therapy will experience biochemical recurrence3 while 
in one third of them metastatic and/or recurrent dis-
ease will be detected within 10 years. The mainstay of 
treatment of metastatic disease for decades was andro-
gen deprivation therapy (Adt) but with a median 
time to failure of only 11 months4. during 10 years 
(2004-2014) several new drugs have been approved for 
the treatment of metastatic castration–resistant pros-
tate cancer (mCRpC) (docetaxel, cabazitaxel, abi-
raterone, enzalutamide, radium-223)5-11. however, 
since 2015 significant advances have been made in the 
treatment of mhSpC and Adt with docetaxel or 
abiraterone has become a new standard of care of mh-
SpC12-16.
Recently, there has been increasing interest in local 
therapy in patients with metastatic prostate cancer. 
This approach has been derived from the idea that the 
primary tumor is a source of metastatic cancer cells 
and a site where resistant clones develop17. moreover, 
in animal models proliferation of tumor cells at distant 
metastatic sites has been dependent on compounds se-
creted by the primary tumor in the circulation18. Re-
cent study has shown multidirectional flow between 
the primary tumor and metastatic sites as well as seed-
ing between metastatic sites in 10 patients with 
mCRpC17. Furthermore, it has been shown that local 
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treatment of the primary tumor can prevent develop-
ment of symptoms19.
Radical local treatment of the primary tumor has 
been studied in several randomized trials and retro-
spective studies in patients with metastatic renal, 
breast, lung and ovarian cancers. nephrectomy im-
proved survival of patients with metastatic renal can-
cer20,21 but that was not confirmed in a more recent 
trial22. Although retrospective studies showed the ben-
efit of the treatment of primary breast cancer23, a ran-
domized study showed no improvement of overall sur-
vival (oS)24. Radiotherapy of the primary tumor did 
not improve oS of patients with metastatic small-cell 
lung cancer in small trial25 while retrospective studies 
showed effectiveness of cytoreductive surgery in ad-
vanced ovarian cancer26.
The aim of this review is to give an overview of the 
literature regarding the role of radiotherapy in meta-
static prostate cancer.
Methods
We performed a review of literature by searching 
medline with the keywords: radiotherapy of metastat-
ic prostate cancer, metastatic hormone-naïve prostate 
cancer and metastatic hormone-sensitive prostate can-
cer. All clinical trials and review articles written in 
english were reviewed. Conference abstracts were also 
included, and cross-matching references were used to 
find additional articles.
Randomized data regarding the prostate radiotherapy 
in hormone-sensitive metastatic prostate cancer
in 2018 two trials, hoRRAd and StAmpede, 
reported a potential survival benefit of adding radio-
therapy to Adt in patients with newly diagnosed low 
volume metastatic disease27,28.
The hoRRAd trial randomized 432 patients with 
newly diagnosed bone metastatic prostate cancer to 
Adt with or without prostate radiotherapy27. meta-
static disease was confirmed by bone-scintigraphy. 
imRt was preferable, but 3d-CRt was also allowed. 
prescribed doses were 70 Gy in 35 fractions of 2 Gy or 
57.76 Gy in 19 fractions of 3.04 Gy, three times a 
week for 6 weeks. A majority of patients (63%) had 
high volume disease i.e. more than 5 osseous metasta-
ses. median follow-up was 47 months. The study 
showed no oS benefit of the addition of prostate ra-
diotherapy. Although not statistically significant, a 
trend toward survival benefit was seen in a low volume 
disease (hR 0.68; 95% Ci 0.42-1.10). The unadjusted 
median time to pSA progression was 15 months in the 
radiotherapy (Rt) group versus 12 months in the con-
trol group (hR 0.78; 95% Ci 0.63-0.97; p = 0.02) but 
after adjustment the hR was no longer significant.
The StAmpede trial28 was a phase 3 trial con-
ducted in 117 centers in Switzerland and the uK from 
January 2013 until September 2016. during that pe-
riod 2061 patients were randomized in 1:1 ratio to re-
ceive either Adt (with or without docetaxel which 
became the new standard of care during the trial) or 
Adt (with or without docetaxel) plus prostate radio-
therapy. metastatic disease was confirmed by bone-
scintigraphy and conventional soft tissue imaging (Ct 
or mRi). median follow-up was 37 months. Radio-
therapy was commenced as practicable after random-
ization or within 3-4 weeks after the last docetaxel 
dose. prescribed dose was 55 Gy in 20 fractions of 2.75 
Gy over 4 weeks or 36 Gy in 6 consecutive weekly 
fractions of 6 Gy. Forty percent of patients had a low 
metastatic burden defined by ChAARted trial (four 
or more bone metastases with one or more outside the 
vertebral body or pelvis, or visceral metastases, or 
both). The results showed no improvement of oS in 
unselected patient group (hR 0.92; 95% Ci 0.80-1.06, 
p = 0.27; median survival 48 months in the Rt group 
vs. 46 months in the control group). however, radio-
therapy significantly improved failure-free survival 
(FFS) (hR 0.76; 95% Ci 0.68-0.84, p < 0.0001; 3-year 
FFS 32% in the Rt group vs. 23% in the control 
group). pre-specified subgroup analysis based on dis-
ease burden was conducted prior to study analysis but 
not prior to accrual. oS was improved in patients with 
a low metastatic burden at baseline who had allocated 
radiotherapy (hR 0.68; 95% Ci 0.52-0.90, p = 0.007; 
3-year oS 81% in the Rt group vs. 73% in the control 
group). The proportion of patients reporting at least 
one severe adverse event (Common terminology Cri-
teria for Adverse events grade 3 or worse) was similar 
between the studied groups (38% in the control group 
vs. 39% in the Rt group). According to the authors of 
the published paper limitations of the study were: 1.) 
retrospective determination of the metastatic burden, 
2.) compliance with allocation to prostate Rt was not 
complete (94%), 3.) median follow-up was shorter 
than median survival.
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prospectively planned StopCAp meta-analysis 
included hoRRAd, StAmped and available re-
sults from ongoing peACe-1 trial29. There was an im-
provement in biochemical progression (hR 0.74; 95% 
Ci 0.67-0.82, p = 0.94 x 10-8) and FFS (hR 0.76; 95% 
Ci 0.69-0.84, p = 0.64 x 10-7), equivalent to ~ 10% 
benefit at 3 years. The effect of prostate radiotherapy 
varied by metastatic burden with 7% improvement in 
3-year survival in men with fewer than 5 bone metas-
tases.
Therefore, the data suggest a significant survival 
benefit of prostate radiotherapy in a low-volume mh-
SpC but the unresolved problem is the lack of exact 
definition of low-volume as well as of oligometastatic 
disease. Although oligometastatic disease was first de-
scribed by hellman and Weichselbaum30 in 1995 and 
the original concept was revised in 2011 to denote dis-
ease limited to specific organ or limited number of 
metastases31, so far no consensus has been reached re-
garding the definition of oligometastatic disease. An-
other issue is the role of more sensitive imaging tech-
niques (eg. 68Ga pSmA pet/Ct, whole body diffu-
sion weighted mRi) since conventional bone and Ct 
scan were used in StAmpede trial. Further, bone 
scans demonstrated to be predictive for the benefit of 
prostate radiotherapy combined with Adt 28.
There are several ongoing clinical trials which are 
investigating prostate radiotherapy in mhSpC. The 
peACe1 is a phase 3 trial (nCt01957436) which is 
consisting of four arms: Adt plus docetaxel; Adt 
plus docetaxel plus abiraterone; Adt plus docetaxel 
plus prostate radiotherapy; and Adt plus docetaxel 
plus abiraterone plus prostate radiotherapy. Another 
phase 3 trial, the SWoG/nCtn trial (nCt03678025) 
will randomize patients to standard systemic therapy 
versus standard systemic therapy and either radical 
prostatectomy or prostate radiotherapy. Similarly, a 
phase 2 trial (nCt01751438) randomizes patients to 
best systemic therapy versus best systemic therapy plus 
either radical prostatectomy or prostate radiotherapy.
The feasibility of prostate surgery in this setting is 
being investigating in the g-RAmmp trial 
(nCt02454543) and the tRomBone trial (iS-
RCtn15704862).
Non-randomized data regarding prostate radiotherapy 
in hormone-sensitive metastatic prostate cancer
non-randomized studies of prostate radiotherapy 
in metastatic prostate cancer are presented in table 1. 
The majority of them indicate that local treatment has 
been associated with better outcome for patients. 
overall survival was improved32 and prostate cancer 
specific mortality (pCaSm) was decreased when in-
tensity modulated radiotherapy (imRt) was applied, 
which was not the case with conformal radiotherapy 
(CRt)33. it has been reported that the potential ben-
efit of local treatment depended on tumor characteris-
tics whit a higher cancer-specific mortality-free sur-
vival rate (CSmFS) in patients with a predicted CSm 
risk < 40%34. in another recent study patients with 
non-regional metastatic lymph nodes and those with 
bone metastases and baseline pSA < 60 ng/ml benefit-
ed from local treatment (radical prostatectomy or 
brachytherapy), while no survival benefit was found 
for patients with other metastatic sites35.
Although it is well known that retrospective data 
should be interpreted cautiously, positive results of 
these studies have encouraged the conduct of random-
ized studies.
Other treatment options in the setting  
of hormone-sensitive metastatic prostate cancer
The addition of docetaxel to Adt significantly im-
proved survival compared to Adt alone in the total 
patient cohort (oS survival benefit of 10.4 months in 
the ChAARted and 15 months in the StAm-
pede trial)12,13. however, only in the ChAARted 
trial13 was stratification based on disease volume and a 
survival benefit was absent in the low-volume disease 
(hR 1.04; 95% Ci 0.70-1.55, p = 0.86). The addition 
of abiraterone and prednisone to Adt also improved 
survival in the lAtitude and StAmpede tri-
als14-16. The lAtitude trial14,15 included patients 
with a high-volume disease defined as two or more of 
the following risk factors: Gleason score ≥ 8, bone le-
sions ≥ 3, visceral metastases. The StAmpede trial16 
also included patients with a low-volume metastatic 
disease as well as patients with locally advanced dis-
ease. Recently published post-hoc analysis of the 
StAmpede trial according to lAtitude criteria 
showed that addition of abiraterone to Adt resulted 
in a 34% reduction in risk of death in a low-volume 
disease (hR 0.66; 95% Ci 0.44-0.98, p = 0.041) and a 
46% reduction in risk of death in a high-volume dis-
ease (hR 0.54; 95% Ci 0.41-0.70, p < 0.001) com-
pared to the Adt alone group36. A retrospective, indi-
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rect comparison of two StAmpede arms i.e. 
docetaxel and abiraterone arm, found no difference in 
oS, prostate cancer-specific survival, metastasis-free 
survival and symptomatic skeletal-related events37. 
FFS and progression-free survival (pFS) were signifi-
cantly better in the abiraterone arm. There were more 
(febrile) neutropenia in the docetaxel arm (13% vs. 
1%) and more cardiovascular disorders in the abi-
raterone arm (9% vs. 3%).
The addition of enzalutamide and apalutamide to 
Adt also showed survival benefit in comparison to 
Adt alone38,39. Their approval is pending.
At the moment, since we have no proven molecular 
biomarkers Belderbos40 et al. suggest clinical factors 
such as metastatic extent and comorbidities to help us 
individualize treatment of patients with mhSpC. in 
the low-volume disease they suggest novel androgen 
receptor (AR) targeted therapies or prostate radiother-
apy while in the high-volume disease they suggest 
docetaxel or abiraterone combined with Adt. in pa-
tients with increased risk of cardiovascular morbidity 
they suggest docetaxel or prostate radiotherapy de-
pending on the metastatic extent of the disease. how-
ever, results of sub-group analysis by metastatic burden 
from long-term follow-up of metastatic patients in the 
StAmpede trial that will be announced shortly 
could possibly have impact on treatment decision.
Metastasis-directed therapy (MDT)  
of oligometastatic disease
prostate cancer mainly spreads to bones and lymph 
nodes, while visceral metastases are rare. local treat-
ment options are surgery, external beam radiotherapy 
(eBRt) and stereotactic body radiation (SBRt). 
There are three scenarios of oligometasatic disease: 
synchronous to the newly diagnosed primary tumor 
(hormone sensitive), oligorecurrence (hormone sensi-
tive) and oligoprogression (castration resistant)41. As a 
local treatment SBRt has been studied little in the 
first scenario, but there are numerous studies in other 
two scenarios with a predominance of retrospective 
studies41. The studies were very heterogeneous in terms 
of patient population, treatment schemes and primary 
endpoints. toxicity was low and local control excellent 
but the impact of such approach upon oS is not 
known. The Stomp trial, a phase 2 trial, was the first 
randomized study exploring the role of mdt com-
pared to standard of care in oligorecurrent patients42. 
Adt-free survival and biochemical relapse-free sur-
vival were longer than in the control group. The oRi-
ole study is the first randomized study to evaluate 
the efficacy of SBRt as measured by quantification of 
circulating tumor cells in hormone sensitive oligomet-
astatic disease. The preliminary results are promising43. 
other clinical trials exploring mdt are ongoing: 
plAton (nCt03784755), CoRe (nCt02759783), 
peACe v (StoRm, nCt03569241), pCS iX 
(nCt685397).
Conclusion
prostate radiotherapy has emerged as a novel treat-
ment option for newly diagnosed low-volume meta-
static prostate cancer. Although numerous retrospec-
tive studies suggested substantial survival benefit, until 
now only one randomized study has shown significant 
survival benefit of prostate radiotherapy in mhSpC 
and that effect was limited only to the group of pa-
tients with the low-volume disease. Therefore, results 
of ongoing studies are eagerly expected to help to bet-
ter elucidate patients who will benefit the most from 
the treatment, the optimal radiation dose and possibly 
the optimal systemic therapy to be combined with the 
local treatment.
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Sažetak
u KoJih BoleSniKA pRimiJeniti RAdioteRApiJu u metAStAtSKom hoRmonAlno  
oSJetlJivom KARCinomu pRoStAte?
V. Bišof
Standard liječenja metastatskog hormonski osjetljivog karcinoma prostate (mhSKp) je androgen deprivirajuća terapija 
(Adt) s docetakselom ili abirateronom. međutim, brojne retrospektivne studije su ukazale na korist od radioterapije prosta-
te. Rezultati male randomizirane studije (hoRRAd) nisu pokazali poboljšanje ukupnog preživljenja kod primjene radiote-
rapije prostate uz Adt, no uočen je trend ka poboljšanju preživljenja kod bolesnika s malim volumenom metastatske bolesti. 
iako rezultati velike randomizirane studije (StAmpede) također nisu pokazali poboljšanje preživljenja u ukupnoj popula-
ciji bolesnika, preživljenje bez neuspjeha liječenja bilo je značajno poboljšano. pored toga, ukupno preživljenje je bilo značaj-
no poboljšano u bolesnika s malim volumenom metastatske bolesti. u nedostatku pouzdanih molekularnih markera, opseg 
metastatske bolesti pojavio se kao važan čimbenik kod odlučivanja o liječenju. u ovom preglednom radu iznosimo rezultate 
ne-randomiziranih i randomiziranih studija o radioterapiji prostate kako bi doprinijeli poboljšanju izbora liječenja za svakog 
pojedinog bolesnika oboljelog od mhSKp s ciljem postignuća najboljeg mogućeg ishoda liječenja.
Ključne riječi: metastatski hormonski osjetljivi karcinom prostate, radioterapija prostate, bolest malog volumena
